Remove Regulations Remove Therapies Remove Treatment
article thumbnail

Exploring Flavonoids as Regulators of MMP‐2 and MMP‐9 in Cancer Pathogenesis

Chemical Biology and Drug Design

Flavonoids exhibit significant potential in cancer therapy by inhibiting MMP-2 and MMP-9 activity and expression, primarily through interactions with their active sites and modulation of the MAPK signaling pathway. ABSTRACT Last few decades, extensive research efforts have been dedicated to uncovering novel cancer treatments.

article thumbnail

Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development

FDA Law Blog: Drug Discovery

Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. The Natural History Studies Grants Program funds natural history studies that collect gather data on how rare diseases progress over time without treatment.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bluebird, playing catch-up, gets decision date for sickle cell gene therapy

BioPharma Drive: Drug Pricing

The regulator will issue a decision on lovo-cel by Dec. 20, roughly two weeks after a verdict is expected on a rival gene editing treatment from Vertex and CRISPR Therapeutics.

Therapies 251
article thumbnail

Logistics in Focus: Orchestrating the Challenges of Cell Therapy

Conversations in Drug Development Trends

By Amy Raymond, PhD, PMP, Executive Director, Therapeutic Strategy Lead, Rare Disease Cell and gene therapies (CGTs) include cutting-edge approaches that offer the hope of a healthier, happier, and better tomorrow for a wide range of patient populations. Below, we discuss some of these challenges in cell therapy trials.

article thumbnail

FDA Approves Label Updates for Bristol Myers Squibb Cell Therapies, Removes REMS

The Pharma Data

FDA Approves Streamlined Monitoring Requirements and REMS Program Removal for Bristol Myers Squibb’s CAR T Cell Therapies Breyanzi and Abecma, Marking Milestone Toward Expanding Access to Cancer Treatment In a significant regulatory development, Bristol Myers Squibb announced that the U.S.

article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

All these features make GPCRs central to regulating many vital biological processes in the body, including immune responses and inflammation, and thus especially attractive for therapeutic intervention. GPCR-targeting therapies such as DT-9046 represent a compelling opportunity in that respect, with major clinical and commercial potential.

Disease 59
article thumbnail

Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis

Covalent Modifiers

BIIB129 (25) demonstrated efficacy in disease-relevant preclinical in vivo models of B cell proliferation in the CNS, exhibits a favorable safety profile suitable for clinical development as an immunomodulating therapy for MS, and has a low projected total human daily dose.

Treatment 208